Enigma Diagnostics' Patents Maintained by UK Intellectual Property Office

OXFORD, England, October 18, 2010 - Enigma Diagnostics Limited, the decentralised and point-of-care molecular
diagnostics company, announced that the UK Intellectual Property Office (IPO)
has rejected a revocation action brought by Biogene against three patents
licensed exclusively to Enigma by the Defence Science and Technology
Laboratory (Dstl), part of the UK Ministry of Defence. The patents cover
electrically conducting polymer (ECP) thermal cycling technology which is
used in Enigma's fully automated real-time PCR system, the Enigma ML, to
enable rapid molecular testing at the point of care.

On 9th August 2010 the IPO issued summary judgement against Biogene and
awarded costs to Dstl. The absence of any subsequent appeal to the High Court
means that these patents are now free from any challenge.

The ECP patents are part of Enigma's extensive intellectual property
portfolio, covering molecular diagnostics and sample preparation
technologies, which comprises of over 350 patent filings including 220
granted cases.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation
rapid molecular diagnostic instrument platforms for decentralized and
point-of-care settings. Enigma's innovative and proprietary technologies
combine the speed and sensitivity of real-time PCR (polymerase chain
reaction) with the simplicity needed for decentralized and point-of-care
testing providing results from a raw sample in less than 60 minutes. The
Company is targeting a number of multi-billion pound markets, core among
which are the Clinical and high-value Applied Markets. Enigma's
commercialisation strategy is to maximize revenues from a continuous flow of
market leading rapid diagnostic point-of care instrument and assay platforms,
based on unique technologies and underpinned by its broad Intellectual
Property portfolio. Enigma will partner with market leaders where global
penetration of markets is required and where appropriate, will engage
regional partners and build in-house sales and marketing capability to direct
distribution of its products.

For more information visit www.enigmadiagnostics.com

    Contact:
    --------
    Josephine Deniau
    Communications Manager
    josephine.deniau@enigmadiagnostics.com
    +971-0-4-446-2367

Josephine Deniau, Communications Manager, josephine.deniau at enigmadiagnostics.com, +971-0-4-446-2367